BioRegenx, Inc.

BRGX: 10-Q · periodic report

BioRegenx reported a net loss of $26,415 for the three months ended March 31, 2026, a significant improvement from the $266,854 loss in the prior year period, driven by a $100,435 write-off of unpayable accrued liabilities and reduced operating expenses. Despite the improved net loss, the company faces severe liquidity constraints with only $45,806 in cash, a stockholders' deficit of $4.5 million, and $522,500 in defaulted debt, including two EIDL loans and older private notes. Management explicitly stated there is substantial doubt about the company's ability to continue as a going concern, noting that continuation depends on obtaining additional debt or equity financing, which may cause substantial dilution. The filing also disclosed material weaknesses in internal controls, including ineffective control environment and insufficient segregation of duties, alongside ongoing litigation with former officers and a distributor.

SEC 10-Q•5mo ago

BRGX: NT 10-Q · late filing

BioRegenx, Inc. (formerly Findit, Inc.) filed a Form 12b-25 notification on May 15, 2026, requesting an extension to file its Form 10-Q for the quarter ended March 31, 2026. The company cited 'unanticipated delays' in completing its audit and preparation of the report as the reason for the inability to file within the prescribed time period. This late filing notification is a bearish signal, often indicating underlying accounting complexities, internal control weaknesses, or financial distress that prevents the timely closing of books.

SEC NT 10-Q•5mo ago